Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II TPF induction chemotherapy followed by cetuximab radioimmunotherapy with IMRT plus carbon ion boost in locally advanced oropharyngeal, hypopharyngeal and laryngeal tumors
2009-016489-10Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- May 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin, fluorouracil and cetuximab in oropharyngeal cancer, hypopharyngeal cancer and laryngeal cancer, sponsored by Heidelberg University. Started May 2010; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilcetuximab
03
Conditions
oropharyngeal cancerhypopharyngeal cancerlaryngeal cancer
Beyond the preview
Go deeper on 2009-016489-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016489-10.